DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pulmonary Disease, Chronic Obstructive

Intervention: fluticasone propionate/salmeterol xinafoate combination (Drug)

Phase: N/A

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Summary

The specific aim of this study is to describe 1 year Advair dispensing rates for patients with COPD, and to measure the association between Advair adherence and healthcare utilization (e. g. emergency room visits and inpatient admissions, etc.). To compare the risk of a COPD exacerbation (moderate or severe) during a 3-month follow-up period between patients thqat are adherent versus those that are not.

Clinical Details

Official title: Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome:

Mean Number of Pharmacy Claims by Participants During the Post-Index Period

Mean Number of Healthcare Encounters Incurred by Participants During the Post-Index Period

Eligibility

Minimum age: 40 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

INCLUSION CRITERIA

- at least one pharmacy claim for Advair (any strength; Diskus or MDI) during the index

year (July 1, 2005 through June 30, 2006).

- Continuous medical and pharmacy eligibility for the 12 month Pre-Index year and the

12 month Index year (referred to as the 24 month Observation Period), and the 3 month Post-Index period (referred to as the Outcome Period).

- At least one medical claim with a diagnosis (either primary or secondary) of COPD

(ICD-9 code 490. xx, 491. xx, 492. xx, and 496), AND at least 1 pharmacy claim for an Anticholinergic medication, both occurring during the12 month pre-index period.

- At least 40 years old at index date.

EXCLUSION CRITERIA

- any medical claim (ever) with a primary or secondary diagnosis of cystic fibrosis

(ICD-9 code 277. 0x).

Locations and Contacts

Additional Information

Starting date: August 2009
Last updated: March 15, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017